Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, October 6, 2026

Back to today

New Position (ONON): Game is On

On Holding (ONON) is gaining sportswear share, expanding store space and launching soccer with Kylian Mbappé as investors debate U.S. consumer weakness and China growth.

ONON $12B
Aurelion Research 4 clicks

From X

@BrokenMoats 1 click

Broken Moats on X

$BFLY the Midjourney ultrasound full body announcement is a highly entertaining read. Sadly I cannot back into what the "ultrasound on a chip" pricing is and what 50,000 units * 40 chips would equate to at Midjourneys target opening in 2031 (as a potential full revenue opportunity). But I do know there are limitations in what ultrasound can scan for versus MRI/CT - their are advantageous for both and why they are used for different imaging needs (pregnancy, organ, blood flow for ultrasound v. skeletal, brain ct) ...So the companies promotion of using ultrasound pools to replace CT is either misleading or an outright lie, it is simply not possible. The story gets worse, they plan on opening spas, with water pools to conduct their scanning. Only doing body composition and no actual medical diagnosis scans to open in SF hopefully in 2027...the maintenance costs will be significant as they have to treat the water before each usage and limits throughput. Plus the renderings imply significant capX that will need to be recouped at some point (either throughput or higher prices than they are leading on). So no idea the propensity of vc funded AI companies to spend irrationally and without regard for economics so perhaps BFLY will be a beneficiary here (seems difficult at their current valuation and the likelihood of Midjourney ever scaling their operation but who knows....) the free spending train rolls on for now. I encourage someone to watch the videos put out by Midjourney its truly something......
@BrokenMoats

Broken Moats on X

Odd two day movement in $KMX after earnings... Agree with the day 1 action - a stock that came into the report on a blistering run, and while the co. reported "improved" results, there are significant challenges still in front of them. Most of the improvement is driven by a dramatic lowering of sale prices to increase sales (gross profit dollars still lower). And that is a lever that will likely remain a permanence as they try and respond to efforts from $CVNA and others. I will credit them on lowering expenses as well, likely low hanging fruit and moves to reduce ("automate") reconditioning again following the caravan playbook of leaving cars closer to as returned. issues on loans remains in a market that is significantly challenged and does not appear on the verge of improving any time soon. The cha cha move Thursday and Friday would argue sets up a better short opportunity in the name as you have removed the IV from earnings to now look out the next few months on put/spreads looking for a cooling off. *even sell side numbers I put little stock in almost all are below, and most significantly from the current price (one could argue thats bullish to rerate but I see this more like Birk that is behaving more like a squeeze than actual fundamentals, hence the wide divergence)
@BrokenMoats

Broken Moats on X

$BSX ?? flat over the past 5 years. Can point to slowing growth from very elevated levels as farapulse and watchman have larger bases, some competition entering these spaces, glp1 on the margin to case loads over time, new inhibitors that could be coming from Lilly, novo, but at current $ sure seems like a lot is baked in at current prices. Innovative cardio franchise that has: Revenue has effectively doubled - predominately from farapulse and watchman (not m&a) Operating income 1.8B to 4.1B EBIT - $1.4B to 4.1B 3.5x on EPS (.69 to $2.40/share current) gross, operating, net, ebit, ebitda margins all expanded over that timeframe FCF more than 2x, opcf 2.5x The difference is you get to buy it at the same share price today, shares outstanding are virtually flat. Perhaps the defensive nature of medtech is sold in the aggressive risk on market we are in but growth still solid here with dividend and margin of safety versus other areas certainly seems worth a look, as is the rest of medtech as a place to hunt for value to wait until the market rotates back

Investor Letters

All letters

Canterra Minerals: Research Note

Canterra Minerals increased Lundberg indicated tonnage 55% to 26.1Mt, with 226.2Kt of contained copper equivalent, supporting a Buchans…

EQX $13B
Atrium Research - Equity Research 1 click

Kenorland Minerals: Research Flash

Franco-Nevada bought 10.0 million Kenorland shares, a 12.4% stake, for C$22.2 million in a secondary transaction that issued no new shares.

FNV $47B
Atrium Research - Equity Research 2 clicks

Solid Power Still Has Promise

Solid Power reported a $0.11 Q2 loss and $419.3 million of cash, with its electrolyte pilot line and BMW and SK On validation central to…

SLDP $473M
Quad 7 Capital 2 clicks
ZOOZ · long

Zooz Strategy LTD

ZOOZ Strategy trades at a roughly 37% discount to the market value of its Bitcoin holdings and cash on a fully diluted basis.

ZOOZ $51M
Value Investors Club 2 clicks

Practical Parametric Yield

Cerebras’s WSE-3 faces parametric-yield constraints that could restrict supply, making power and clock-speed tradeoffs central to its next…

CBRS $33B
Irrational Analysis 3 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 108

YouTube 4

Blogs 17

Seeking Alpha 52 of 240

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

89 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.